Press Releases

Press Releases

May 29, 2019
SOUTH SAN FRANCISCO, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at three investor
May 7, 2019
Initiated ALLO-501 Phase 1 ALPHA Trial in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma ( NHL ) Investigational New Drug (IND) Application Submitted to the U.S. Food & Drug Administration ( FDA ) for ALLO-715 Targeting BCMA for the Treatment of Patients with Relapsed/Refractory Multiple
May 1, 2019
Newly Appointed Members Include Robert Abraham, Ph.D., Malcolm K. Brenner, M.D., Ph.D., Stephen J. Forman, M.D., and Wendell Lim, Ph.D. SOUTH SAN FRANCISCO, Calif. , May 01, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the
April 15, 2019
Anti-BCMA AlloCAR T Cells Maintained Phenotype and Sustained Potent Anti-Tumor Responses After Scaled-Up Manufacturing ALLO-715 Investigational New Drug Application and Phase 1 Trial Initiation Expected in 2019 SOUTH SAN FRANCISCO, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics,
April 3, 2019
SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Jefferies
Displaying 1 - 10 of 13
Print Page
E-mail Alerts
RSS
Investor Contacts